Galecto doses last patient in lung disease trial
Topline data from a phase II trial in idiopathic pulmonary fibrosis may be presented as soon as August, the company informs.
by albert rønning-andersson, translated by daniel pedersen & christian radich hoffman
Galecto Biotech has now treated all of the 144 patients that were enrolled in a phase IIb trial of drug candidate GB0139, a potential treatment for idiopathic pulmonary fibrosis (IPF).
Already a subscriber?Log in here
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
With your free trial you get:
- Access all locked articles
- Receive our daily newsletters
- Access our app
Get full access for you and your coworkers
Start a free company trial todayRelated articles:
Galecto begins third phase II trial
For subscribers
